Trevena (TRVN) : 6-year performance

Trevena (TRVN) : 4-year performance

Trevena (TRVN) began trading on the NASDAQ on 31 January 2014

Two months after postponing its proposed initial public stock offering because of unfavorable market conditions, Trevena Inc. will be trading on NASDAQ.

The King of Prussia, PA biopharmaceutical company will begin trading Friday in a $64.75 million IPO. It is selling 9.25 million shares of common stock at $7 per share.

Trevena’s focus is on developing the next generation of medicines that target G-protein coupled receptors (GPCRs). GPCRs are a large family of cell surface receptors that trigger signaling pathways linked to cellular function and disease processes. The The 6-year-old company’s “biased” GPCR ligands work by binding to receptors that are “biased” toward either activating or blocking specific signaling pathways to treat a disease.

Trevena, according to its SEC filing, plans to use the bulk of its proceeds from the proposed stock offering to continue the development of its two lead drug candidates: TRV027, an acute heart failure treatment, and TRV130, a treatment of moderate-to-severe acute pain. It also plans to advance additional product candidates, including two preclinical programs focused on central nervous system indications.

The company, led by CEO Maxine Gowen, has granted the underwriters a 30-day option to purchase up to 1.4 million additional shares of common stock to cover overallotments. The offering is expected to close on February 5, 2014, subject to customary closing conditions.

Barclays Capital and Jefferies are joint book-running managers for the offering. Canaccord Genuity Inc., JMP Securities and Needham & Co. are acting as co-managers.

From those keeping track at home, Trevena's stock sale makes four initial public stock offerings by Philadelphia region’s life sciences company since last summer.

Onconova Therapeutics of Newtown, Pa., and TetraLogic Pharmaceuticals of Malvern, Pa., completed IPO’s last year. Akers Biosciences Inc. of Thorofare, N.J., raised $15 million in a public stock offering that put the company’s stock on NASDAQ. It previously traded only on the London Stock Exchange.

Address

Suite A, 1018 West 8th Avenue
KNG OF PRUSSA, PA 19406
United States

Website  

http://www.trevenainc.com

Key stats and ratios

	Q3 (Sep '13)	2012
Net profit margin	-	-1936.07%
Operating margin	-	-1932.89%
EBITD margin	-	-1835.38%
Return on average assets	-65.90%	-113.73%
Return on average equity	-	-
Employees	31

Trevena Announces Pricing of Initial Public Offering

KING OF PRUSSIA, Pa., Jan 31, 2014 (BUSINESS WIRE) -- Trevena, Inc., a clinical stage pharmaceutical company involved in the discovery and development of G protein coupled receptor (GPCR) biased ligands, today announced the pricing of its initial public offering of 9,250,000 shares of common stock at a price of $7.00 per share. Trevena previously announced that the number of shares in the offering was 8,500,000. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "TRVN" on January 31, 2014. In addition, Trevena has granted the underwriters a 30-day option to purchase up to 1,387,500 additional shares of common stock from Trevena at the initial public offering price. The offering is expected to close on February 5, 2014, subject to customary closing conditions.

Barclays Capital Inc. and Jefferies LLC are acting as joint book-running managers for the proposed offering. Canaccord Genuity Inc., JMP Securities LLC and Needham & Company, LLC are acting as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 30, 2014.

The offering is being made only by means of a prospectus. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at Barclaysprospectus@broadridge.com or by phone at 888-603-5847 or Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Trevena

Trevena, Inc. is a clinical stage biopharmaceutical company that discovers, develops and intends to commercialize therapeutics that use a novel approach to target G protein coupled receptors, or GPCRs. Using its proprietary product platform, Trevena has identified and advanced two differentiated product candidates into the clinic -- TRV027 to treat acute heart failure and TRV130 to treat moderate to severe acute pain intravenously. Trevena also plans to advance additional product candidates, including two preclinical programs focused on central nervous system indications.

Trevena

King of Prussia, Pa.
Founders: Dr. Robert Lefkowitz and Dr. Howard Rockman
VC Investment over the last four quarters: $26.1 million

Trevena, founded in January 2008, is a drug discovery company developing pharmaceuticals that target what are known as G-protein coupled receptors. Such drugs make up more than 40% of marketed drugs today, according to Trevena. The company's drug discovery platform is based on research from Duke University Medical Center, including that of founder and National Medal of Science winner Robert Lefkowitz.